Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer

Yoon Ah Park, Seung Kook Sohn, Jinsil Seong, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim, Chang Whan Cho

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background and Objectives: Recent data suggest that good responders to preoperative chemoradiation (CRT) have a favorable prognosis in rectal cancer patients. The aim of this study was to investigate the predictive value of serum carcinoembryonic antigen (CEA) levels for the tumor response to preoperative CRT in rectal cancer patients. Methods: The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery. The staging workup was consisted of endorectal ultrasound, abdominopelvic computed tomography scan, or magnetic resonance imaging. The outcome parameters were cancer-specific survival and disease-free survival. Pre-CRT clinicopathologic features, including age, gender, location of the tumor, clinical tumor (cT) classification, clinical nodal (cN) classification, and serum CEA levels were investigated as possible predictors for the response to preoperative CRT. Results: Pathologic complete or near complete responses (good responders, GR) occurred in 26 (19%) patients, while partial or no response (poor responders, PR) occurred in the remaining 115 (81%) patients. GR showed better cancer-specific survival (P = 0.028) and disease-free survival rates (P = 0.011) than PR. Univariate analysis revealed that positive cN and elevated (>5 ng/ml) pre-CRT serum CEA levels are associated with poor tumor response to preoperative CRT. Using logistic regression analysis, elevated pre-CRT serum CEA levels were the only significant predictor for the poor response to CRT (Odd ratio = 2.876, 95% confidence interval = 1.04-7.46, P = 0.041). Conclusions: Our data suggest that elevated pre-CRT serum CEA levels are associated with poor tumor response to CRT. Therefore, pre-CRT serum CEA levels provide useful information about tumor response to preoperative CRT in rectal cancer patients.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalJournal of surgical oncology
Volume93
Issue number2
DOIs
Publication statusPublished - 2006 Feb 1

Fingerprint

Carcinoembryonic Antigen
Rectal Neoplasms
Serum
Neoplasms
Disease-Free Survival
Survival
Fluorouracil
Adenocarcinoma
Radiotherapy
Survival Rate
Logistic Models
Odds Ratio
Tomography
Regression Analysis
Magnetic Resonance Imaging
Confidence Intervals
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Park, Yoon Ah ; Sohn, Seung Kook ; Seong, Jinsil ; Baik, Seung Hyuk ; Lee, Kang Young ; Kim, Nam Kyu ; Cho, Chang Whan. / Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. In: Journal of surgical oncology. 2006 ; Vol. 93, No. 2. pp. 145-150.
@article{84659cb937074f629b225cfa0a2f2f4f,
title = "Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer",
abstract = "Background and Objectives: Recent data suggest that good responders to preoperative chemoradiation (CRT) have a favorable prognosis in rectal cancer patients. The aim of this study was to investigate the predictive value of serum carcinoembryonic antigen (CEA) levels for the tumor response to preoperative CRT in rectal cancer patients. Methods: The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery. The staging workup was consisted of endorectal ultrasound, abdominopelvic computed tomography scan, or magnetic resonance imaging. The outcome parameters were cancer-specific survival and disease-free survival. Pre-CRT clinicopathologic features, including age, gender, location of the tumor, clinical tumor (cT) classification, clinical nodal (cN) classification, and serum CEA levels were investigated as possible predictors for the response to preoperative CRT. Results: Pathologic complete or near complete responses (good responders, GR) occurred in 26 (19{\%}) patients, while partial or no response (poor responders, PR) occurred in the remaining 115 (81{\%}) patients. GR showed better cancer-specific survival (P = 0.028) and disease-free survival rates (P = 0.011) than PR. Univariate analysis revealed that positive cN and elevated (>5 ng/ml) pre-CRT serum CEA levels are associated with poor tumor response to preoperative CRT. Using logistic regression analysis, elevated pre-CRT serum CEA levels were the only significant predictor for the poor response to CRT (Odd ratio = 2.876, 95{\%} confidence interval = 1.04-7.46, P = 0.041). Conclusions: Our data suggest that elevated pre-CRT serum CEA levels are associated with poor tumor response to CRT. Therefore, pre-CRT serum CEA levels provide useful information about tumor response to preoperative CRT in rectal cancer patients.",
author = "Park, {Yoon Ah} and Sohn, {Seung Kook} and Jinsil Seong and Baik, {Seung Hyuk} and Lee, {Kang Young} and Kim, {Nam Kyu} and Cho, {Chang Whan}",
year = "2006",
month = "2",
day = "1",
doi = "10.1002/jso.20320",
language = "English",
volume = "93",
pages = "145--150",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. / Park, Yoon Ah; Sohn, Seung Kook; Seong, Jinsil; Baik, Seung Hyuk; Lee, Kang Young; Kim, Nam Kyu; Cho, Chang Whan.

In: Journal of surgical oncology, Vol. 93, No. 2, 01.02.2006, p. 145-150.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer

AU - Park, Yoon Ah

AU - Sohn, Seung Kook

AU - Seong, Jinsil

AU - Baik, Seung Hyuk

AU - Lee, Kang Young

AU - Kim, Nam Kyu

AU - Cho, Chang Whan

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Background and Objectives: Recent data suggest that good responders to preoperative chemoradiation (CRT) have a favorable prognosis in rectal cancer patients. The aim of this study was to investigate the predictive value of serum carcinoembryonic antigen (CEA) levels for the tumor response to preoperative CRT in rectal cancer patients. Methods: The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery. The staging workup was consisted of endorectal ultrasound, abdominopelvic computed tomography scan, or magnetic resonance imaging. The outcome parameters were cancer-specific survival and disease-free survival. Pre-CRT clinicopathologic features, including age, gender, location of the tumor, clinical tumor (cT) classification, clinical nodal (cN) classification, and serum CEA levels were investigated as possible predictors for the response to preoperative CRT. Results: Pathologic complete or near complete responses (good responders, GR) occurred in 26 (19%) patients, while partial or no response (poor responders, PR) occurred in the remaining 115 (81%) patients. GR showed better cancer-specific survival (P = 0.028) and disease-free survival rates (P = 0.011) than PR. Univariate analysis revealed that positive cN and elevated (>5 ng/ml) pre-CRT serum CEA levels are associated with poor tumor response to preoperative CRT. Using logistic regression analysis, elevated pre-CRT serum CEA levels were the only significant predictor for the poor response to CRT (Odd ratio = 2.876, 95% confidence interval = 1.04-7.46, P = 0.041). Conclusions: Our data suggest that elevated pre-CRT serum CEA levels are associated with poor tumor response to CRT. Therefore, pre-CRT serum CEA levels provide useful information about tumor response to preoperative CRT in rectal cancer patients.

AB - Background and Objectives: Recent data suggest that good responders to preoperative chemoradiation (CRT) have a favorable prognosis in rectal cancer patients. The aim of this study was to investigate the predictive value of serum carcinoembryonic antigen (CEA) levels for the tumor response to preoperative CRT in rectal cancer patients. Methods: The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery. The staging workup was consisted of endorectal ultrasound, abdominopelvic computed tomography scan, or magnetic resonance imaging. The outcome parameters were cancer-specific survival and disease-free survival. Pre-CRT clinicopathologic features, including age, gender, location of the tumor, clinical tumor (cT) classification, clinical nodal (cN) classification, and serum CEA levels were investigated as possible predictors for the response to preoperative CRT. Results: Pathologic complete or near complete responses (good responders, GR) occurred in 26 (19%) patients, while partial or no response (poor responders, PR) occurred in the remaining 115 (81%) patients. GR showed better cancer-specific survival (P = 0.028) and disease-free survival rates (P = 0.011) than PR. Univariate analysis revealed that positive cN and elevated (>5 ng/ml) pre-CRT serum CEA levels are associated with poor tumor response to preoperative CRT. Using logistic regression analysis, elevated pre-CRT serum CEA levels were the only significant predictor for the poor response to CRT (Odd ratio = 2.876, 95% confidence interval = 1.04-7.46, P = 0.041). Conclusions: Our data suggest that elevated pre-CRT serum CEA levels are associated with poor tumor response to CRT. Therefore, pre-CRT serum CEA levels provide useful information about tumor response to preoperative CRT in rectal cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=32544447094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544447094&partnerID=8YFLogxK

U2 - 10.1002/jso.20320

DO - 10.1002/jso.20320

M3 - Article

C2 - 16425302

AN - SCOPUS:32544447094

VL - 93

SP - 145

EP - 150

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -